Skip to main content

Table 7 MMP content and levels of T cell subsets before and after treatment in patients with different subtypes of lung cancer in the test group

From: Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer

Project SCLC NSCLC P Value LADC LSCC P Value
Before treatment
 MMP-2 (ng/L) 182.93 ± 12.24 181.52 ± 11.67 0.48 180.22 ± 10.37 181.05 ± 12.14 0.65
 MMP-9 (ng/L) 206.17 ± 21.43 207.88 ± 21.86 0.64 207.61 ± 21.59 208.20 ± 21.54 0.87
 CD4+% 33.63 ± 3.76 33.00 ± 4.09 0.36 32.55 ± 3.64 33.17 ± 3.93 0.32
 CD8+% 30.87 ± 3.03 30.46 ± 3.34 0.46 30.25 ± 3.13 30.77 ± 3.03 0.31
 CD4+/CD8+ 1.20 ± 0.22 1.15 ± 0.23 0.20 1.17 ± 0.21 1.13 ± 0.21 0.25
After treatment
 MMP-2 (ng/L) 35.6 ± 1.02 30.52 ± 2.12 < 0.0001 30.71 ± 2.31 30.78 ± 1.86 0.85
 MMP-9 (ng/L) 35.37 ± 1.25 31.08 ± 1.52 < 0.0001 31.13 ± 1.47 30.86 ± 1.3 0.25
 CD4+% 38.15 ± 4.97 37.78 ± 5.08 0.66 37.33 ± 4.63 37.81 ± 5.05 0.54
 CD8+% 27.22 ± 3.66 26.93 ± 3.71 0.64 26.51 ± 3.29 27.13 ± 3.51 0.27
 CD4+/CD8+ 1.36 ± 0.18 1.33 ± 0.21 0.39 1.30 ± 0.18 1.34 ± 0.20 0.20
\